Rigel Pharmaceuticals (RIGL) Competitors $38.91 -0.40 (-1.02%) As of 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. FOLD, BCRX, CLDX, NVAX, INVA, MNKD, DVAX, OPK, GERN, and ZBIOShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), MannKind (MNKD), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Its Competitors Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva MannKind Dynavax Technologies OPKO Health Geron Zenas BioPharma Rigel Pharmaceuticals (NASDAQ:RIGL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Do insiders & institutionals have more ownership in RIGL or FOLD? 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 9.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, RIGL or FOLD? Rigel Pharmaceuticals has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Do analysts recommend RIGL or FOLD? Rigel Pharmaceuticals presently has a consensus price target of $38.20, indicating a potential downside of 1.82%. Amicus Therapeutics has a consensus price target of $16.22, indicating a potential upside of 114.15%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer RIGL or FOLD? In the previous week, Amicus Therapeutics had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Amicus Therapeutics and 4 mentions for Rigel Pharmaceuticals. Amicus Therapeutics' average media sentiment score of 1.25 beat Rigel Pharmaceuticals' score of 0.63 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is RIGL or FOLD more profitable? Rigel Pharmaceuticals has a net margin of 36.51% compared to Amicus Therapeutics' net margin of -6.67%. Rigel Pharmaceuticals' return on equity of 438.89% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals36.51% 438.89% 57.03% Amicus Therapeutics -6.67%-5.07%-1.23% Which has higher earnings and valuation, RIGL or FOLD? Rigel Pharmaceuticals has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$267.92M2.60$17.49M$5.417.19Amicus Therapeutics$528.29M4.42-$56.11M-$0.12-63.13 SummaryRigel Pharmaceuticals beats Amicus Therapeutics on 9 of the 16 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$695.24M$2.53B$5.76B$9.75BDividend YieldN/A1.68%3.95%4.02%P/E Ratio7.1622.6331.4526.36Price / Sales2.60535.60431.04155.09Price / Cash36.83177.0937.7559.42Price / Book8.515.9510.536.57Net Income$17.49M$32.94M$3.28B$265.92M7 Day Performance-6.24%-1.64%0.37%0.06%1 Month Performance95.53%1.93%5.15%1.99%1 Year Performance187.16%10.64%50.24%20.91% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals1.6122 of 5 stars$38.91-1.0%$38.20-1.8%+204.7%$695.24M$267.92M7.16160FOLDAmicus Therapeutics4.3051 of 5 stars$7.48-1.7%$16.22+116.9%-31.8%$2.35B$528.29M-62.33480Positive NewsBCRXBioCryst Pharmaceuticals4.2503 of 5 stars$8.39-2.0%$16.70+99.0%-0.9%$1.80B$450.71M-46.61530Positive NewsCLDXCelldex Therapeutics1.8359 of 5 stars$21.93-2.4%$46.67+112.8%-41.8%$1.49B$7.02M-7.29150NVAXNovavax4.4727 of 5 stars$7.52-4.1%$15.57+107.1%-31.9%$1.27B$682.16M3.301,990Trending NewsAnalyst ForecastAnalyst RevisionINVAInnoviva4.4886 of 5 stars$19.76-2.0%$42.75+116.3%+4.5%$1.27B$358.71M63.74100Positive NewsMNKDMannKind3.4101 of 5 stars$3.90-5.1%$9.71+149.1%-23.9%$1.26B$285.50M35.46400Analyst ForecastDVAXDynavax Technologies4.6292 of 5 stars$10.39-1.0%$24.33+134.2%-6.7%$1.23B$277.25M-22.59350OPKOPKO Health4.4294 of 5 stars$1.39-1.4%$2.75+97.8%-13.9%$1.12B$713.10M-5.562,997News CoveragePositive NewsGERNGeron3.1009 of 5 stars$1.42-2.7%$4.19+194.9%-68.3%$931.51M$76.99M-10.92229ZBIOZenas BioPharma1.5463 of 5 stars$16.56-3.2%$36.67+121.4%N/A$720.09M$5M0.00N/A Related Companies and Tools Related Companies Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Novavax Alternatives Innoviva Alternatives MannKind Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Zenas BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access